FDA Law Blog

SEPTEMBER 26, 2023

(HP&M), a leader in providing legal and regulatory support to the life sciences industries, today announced the appointment of Jeff Grizzel to the newly created position of Chief Marketing Officer (CMO). Jeff joins HP&M from Compliance Architects where he served as Vice President of Business Development.

Marketing 59

Marketing Life Science Compliance Business Development 59

pharmaphorum

AUGUST 8, 2022

As we reported this morning, the deal gives Pfizer already-approved SCD therapy Oxbryta (voxelator) – which industry watchers reckon could see a dramatic uptick in sales with Pfizer’s marketing muscle – plus a phase 3 antibody candidate, a phase 1 follow-up to Oxbryta that could offer improved dosing.

Marketing 111

Marketing Sales Gene Editing Antibody 111

Crucial Data Soutions

JUNE 27, 2022

After experiencing significant growth in the clinical trial solutions market in 2021, Crucial Data Solutions has added another industry veteran to its leadership team. brings over 25 years of sales and leadership experience, the majority of which have been in start-up and emerging growth technology companies. Brian Dufresne, B.S.,

Business Development 52

Business Development Development Clinical Trials Clinical Trials 52

Pharmaceutical Technology

SEPTEMBER 14, 2022

More than 100 approved peptide-based therapeutics are currently available in the market. The increasing demand for API peptide products is in turn increasing the demand for peptide API manufacturers who also offer contract marketing services. Discover the top API protein and peptide companies in contract marketing.

Protein 130

Protein Marketing Manufacturing Reagent 130

BioPharma Reporter

NOVEMBER 21, 2023

OSP was delighted to talk to Vetterâs Carsten Press, a senior leader of the global sales organization, and business development among many operational functions.

Branding 93

Branding Business Development Sales Development 93

pharmaphorum

APRIL 30, 2021

Pharmaceutical sales were flat on the same period of 2020 at $10.7 billion, with vaccines sales falling nearly 19% to $1.8 “We intend to use that capital both for business development and potentially share repurchase, but our clear priority is business development,” said Davis on the Q1 call.

Sales 88

Sales Vaccination Vaccine Business Development 88

Pharmaceutical Technology

AUGUST 30, 2022

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.

Development 130

Development Drugs Bioavailability Production 130

pharmaphorum

JANUARY 28, 2021

It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients.

Marketing 114

Marketing Insulin HR Production 114

Pharmaceutical Technology

JULY 1, 2022

The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. The partnership with Royalty Pharma monetises royalty payments obtainable from net sales of Gavreto by Roche outside of the US, excluding Greater China.

Medicine 147

Medicine Business Development Sales Life Science 147

Pharmaceutical Technology

SEPTEMBER 5, 2022

Wholesale pharmaceutical companies also offer services such as end formulation contracts, which help pharmaceutical marketing companies and pharmacies locate manufacturing units across regions and coordinate negotiations when required. Services, such as customer relationship management (CRM), and after-sales service.

Packaging 130

Packaging Packaging Compliance Manufacturing 130

pharmaphorum

OCTOBER 1, 2021

It has made Oxford Nanopore’s chief executive and cofounder Gordon Sanghera an on-paper fortune of £63 million, while another cofounder – chief business development officer Spike Willcocks – is now worth £30 million. The post Oxford Nanopore makes stellar debut on UK stock market appeared first on.

Marketing 52

Marketing Business Development Genome Genomics 52

Pharmaceutical Technology

MARCH 10, 2023

The pharmaceutical freeze-drying systems market is expected to be driven by the integration of smarter technologies in lyophilisation methods such as electron microscopy, biochemistry, and advancement in surgeries.

Manufacturing 147

Manufacturing Production Containment Antibody 147

pharmaphorum

JANUARY 25, 2023

Life sciences marketing has rapidly evolved to mirror that of consumer retail. Life sciences commercial teams need a way to automate the development of insights surrounding HCP personalisation to avoid expending countless resources in marketing optimisation initiatives.

Life Science 98

Life Science Sales Marketing Production 98

pharmaphorum

SEPTEMBER 30, 2021

The $180-per-share deal – if completed – will give Merck a pair of blockbuster drug candidates, one of which is already on the market, and help to reduce its reliance on $14.4 Sales of Reblozyl were $240 million in the first half of the year, as booked by BMS, with Acceleron claiming a $48 million share of the total.

Sales 116

Sales Pharma Companies Marketing Business Development 116

pharmaphorum

MARCH 9, 2021

Nearly 70% of HCPs are now digital natives, with no interest in going back to pre-COVID sales engagement methods. Pre-COVID, digital sales engagement was mainly about emails – both reps-triggered emails that tended to be more personal and email campaigns prepared by HQ teams. Market pressures. Achieving digital excellence.

Sales 131

Sales Doctors Doctor Marketing 131

pharmaphorum

MAY 17, 2022

Field forces are being realigned, business development re-focussed and digital channels maximised in a new era of sales and engagement. Coaching is now playing a pivotal role in driving better practice and sales performance and it is having an added benefit of boosting employee satisfaction, according to experts.

Sales 72

Sales Production Business Development Development 72

pharmaphorum

JULY 1, 2022

Sixth Street is paying the biotech $250 million upfront for a share of future royalties on Ayvakit and follow-up BLU-263, in a deal that also provides up to $660 million in credit facilities that can be used for business development. Blueprint is drawing $150 million of that straight away. billion if needed. billion if needed.

Business Development 52

Business Development Medicine Sales Marketing 52

Drug Discovery World

NOVEMBER 2, 2022

GSK has announced strong quarterly results, reporting sales of £7.8 billion and growth in various sectors of the business. . The quarterly results are for the first for GSK since it separated its consumer healthcare business, making GSK a pure-play therapeutics company. Vaccines . billion, representing a growth of 9% CER.

Sales 52

Sales Vaccination Vaccine Medicine 52

pharmaphorum

AUGUST 30, 2022

In July, Diurnal reported product sales of around £2.3 The Cardiff-based company’s pipeline also includes an oral testosterone in clinical trials for hypogonadism, as well as a modified-release levothyroxine for hypothyroidism and oligonucleotide-based therapy for Cushing’s disease in preclinical development.

Hormones 105

Hormones Sales Clinical Trials Clinical Trials 105

Pharmaceutical Technology

SEPTEMBER 7, 2022

The rising incidence of long-standing diseases such as hypertension, diabetes, cardiovascular diseases, and cancer requires prolonged medication and, thus, drives the growth and need for retail pharmacies in the market.

Pharmacy 147

Pharmacy Generic Drugs Containment Production 147

XTalks

JUNE 14, 2023

Its specialized project marketplace, known as PartnerMatch, serves as an effective tool for stakeholders on both the supply and demand sides, enabling them to locate partners and enhance collaboration within the globally expansive consumer packaged goods market, valued in the trillions. This is where San Francisco-based PartnerSlate comes in.

Contract Manufacturing 98

Contract Manufacturing Manufacturing Branding Packaging 98

Pharmaceutical Technology

JULY 29, 2022

The most common marketed drugs in this space aim to address the hyperammonaemia caused by the defective genes in this disorder. Drugs for dialysis, amino acid supplements, and drugs which convert blood ammonia are marketed right now as the go-to urea cycle disorder treatments. Future Possibilities.

RNA 245

RNA Gene Expression Gene Gene Therapy 245

XTalks

MAY 29, 2024

The Financial Times’ list of the Americas’ Fastest Growing Companies 2024 provides an insight into the market’s leaders in terms of growth, highlighting not the size of companies but their capacity for innovation. The list features companies from all spheres such as IT, Marketing, Finance and more.

Medicine 52

Medicine Marketing FDA Approval Development 52

Drug Discovery World

MARCH 29, 2023

Julian Collins, Jana Windt and Michiel Stork, ProBioGen Julian Collins has been appointed as Senior Vice President, Head of People & Organizational Development (P&OD) and a member of the Executive Team. John A Dawson, Chairman, ViroCell Biologics John Dawson was Chief Executive Officer of Oxford Biomedica from 2008 to 2022.

Life Science 52

Life Science DNA Business Development Drugs 52

The Pharma Data

JANUARY 12, 2021

Ross is an accomplished life science sales leader with 18 years of experience in strategic account management, business development, and demonstrated excellence in leading cross-functional teams to develop commercial processes and best practices. View source version on businesswire.com: [link]. Source link.

Life Science 40

Life Science Sales Production Business Development 40

Drug Discovery World

MAY 29, 2024

Dr Neela Patel, Chief Business Officer at Bonum Therapeutics, offers advice on how to negotiate a winning deal in biopharma that meets investors’, buyers’ and sellers’ goals. I was chief business development officer at Good at the time, and along with Good’s CEO and founder John Mulligan, I led negotiations for the sale.

Scientist 59

Scientist Licensing Licensing Development 59

The Pharma Data

MARCH 17, 2021

Nally, chief marketing officer, Human Health, will leave the company at the end of March, and Frank Clyburn, chief commercial officer, Human Health, will become president, Human Health and lead all Human Health commercial and marketing for the company. Nally is leaving Merck for a leadership opportunity with another company. “As

Marketing 52

Marketing Business Development Sales Manufacturing 52

The Pharma Data

MAY 18, 2021

Our Crop Science Division achieved encouraging sales growth in an improved market environment. Sales at Pharmaceuticals were steady, and in the Consumer Health Division we performed better than the competition.” Group sales in the first quarter rose by 2.8 Group sales in the first quarter rose by 2.8

Sales 40

Sales Production Marketing Containment 40

pharmaphorum

MAY 18, 2022

billion in potential milestone payments plus royalties on sales. Kelun Pharma said that the deal would accelerate its entry into international markets. The US pharma group is paying $47 million in upfront payments to license rights to the undisclosed drug outside China, Hong Kong, Macao, and Taiwan, with another $1.36

Drugs 59

Drugs Antibody Licensing Licensing 59

XTalks

AUGUST 22, 2022

What sets Auvelity apart from other antidepressants on the market is its ability to act rapidly. Additionally, Axsome says Auvelity is the first oral MDD medication with a new mechanism of action to hit the market in more than 60 years. The med brought in $58 million in sales last year for Jazz.

FDA Approval 98

FDA Approval Production Marketing Drugs 98

pharmaphorum

MARCH 2, 2021

Sandy Lee, senior account director and social media lead, joins bringing expertise in content marketing, business development, social media and digital strategic counsel. With 20 years of advertising experience, Hubert has run campaigns for blue chip companies including EY (Ernst & Young), HSBC, Audi and Eurostar.

Branding 102

Branding Business Development Marketing Development 102

pharmaphorum

JANUARY 14, 2022

was senior vice president of business development, expanding the sales team and establishing key partnerships to meet the needs of sponsors. We lead with a product development mindset, strategically blending clinical development, medical affairs and commercial capabilities to address modern market realities.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Compliance 98

Pharmaceutical Technology

DECEMBER 22, 2022

Financing recognises companies and institutions that have raised significant capital during the research period whether it be through corporate finance, the capital markets or fund raising. What all the ranked entities have in common is the demonstration of new concepts not just within their own business but in the sector as a whole.

Insulin 130

Insulin Production Development Genetics 130

pharmaphorum

JANUARY 12, 2023

The life sciences unit of Google parent Alphabet – which raised $1 billion back in September to fund its precision health agenda and business development activities, including possible acquisitions – said the move would allow it to streamline its operations.

Drug Delivery 69

Drug Delivery Life Science Production Engineer 69

The Pharma Data

APRIL 6, 2022

“With our portfolio of in-market medicines and up to 20 major pipeline assets that could be approved by 2026, Novartis is in a strong position to deliver above-peer-median sales and margin growth in the mid- and long-term.” ” Integrating Pharmaceuticals and Oncology business units.

Medicine 52

Medicine Sales Development Marketing 52

Drug Discovery World

JUNE 29, 2023

Hatton will lead the Medical Analytics Practice vision, with responsibility for continuing to embed the latest digital innovations and advanced analytics practices across the business. Hasan Hallaq, European Sales Director, Victoria Ordsmith, Director of Marketing, and Sarennah Longworth-Cook, Director of People, H.E.L

Drugs 52

Drugs Gene Therapy Development Clinical Trials 52

pharmaphorum

APRIL 25, 2022

Aaron Gani, founder and CEO of BehaVR, and Krys Zaluski, director of business development, digital health at Sumitomo Dainippon Pharma, discuss their groundbreaking partnership to develop and commercialise digital therapeutics (DTx) products. . BehaVR will also receive tiered royalties from global sales of its DTx products.

Behavioural Health 105

Behavioural Health Production Clinical Trials Clinical Trials 105